Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

J.M. Baeten, D. Donnell, P. Ndase, N.R. Mugo, J.D. Campbell, J. Wangisi, J.W. Tappero, E.A. Bukusi, C.R. Cohen,
E. Katabira, A. Ronald, E. Tumwesigye, E. Were, K.H. Fife, J. Kiarie, C. Farquhar, G. John-Stewart, A. Kakia, J. Odoyo,
A. Mucunguzi, E. Nakku-Joloba, R. Twesigye, K. Ngure, C. Apaka, H. Tamooh, F. Gabona, A. Mujugira,
D. Panteleeff, K.K. Thomas, L. Kidoguchi, M. Krows, J. Revall, S. Morrison, H. Haugen, M. Emmanuel-Ogier,
L. Ondrejcek, R.W. Coombs, L. Frenkel, C. Hendrix, N.N. Bumpus, D. Bangsberg, J.E. Haberer, W.S. Stevens,
J.R. Lingappa, and C. Celum, for the Partners PrEP Study Team*

ABSTRACT

BACKGROUND

Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations.

METHODS

We conducted a randomized trial of oral antiretroviral therapy for use as preexposure prophylaxis among HIV-1–serodiscordant heterosexual couples from Kenya and Uganda. The HIV-1–seronegative partner in each couple was randomly assigned to one of three study regimens — once-daily tenofovir (TDF), combination tenofovir–emtricitabine (TDF–FTC), or matching placebo — and followed monthly for up to 36 months. At enrollment, the HIV-1–seropositive partners were not eligible for antiretroviral therapy, according to national guidelines. All couples received standard HIV-1 treatment and prevention services.

RESULTS

We enrolled 4758 couples, of whom 4747 were followed: 1584 randomly assigned to TDF, 1579 to TDF–FTC, and 1584 to placebo. For 62% of the couples followed, the HIV-1–seronegative partner was male. Among HIV-1–seropositive participants, the median CD4 count was 495 cells per cubic millimeter (interquartile range, 375 to 662). A total of 82 HIV-1 infections occurred in seronegative participants during the study, 17 in the TDF group (incidence, 0.65 per 100 person-years), 13 in the TDF–FTC group (incidence, 0.50 per 100 person-years), and 52 in the placebo group (incidence, 1.99 per 100 person-years), indicating a relative reduction of 67% in the incidence of HIV-1 with TDF (95% confidence interval [CI], 44 to 81; P<0.001) and of 75% with TDF–FTC (95% CI, 55 to 87; P<0.001). Protective effects of TDF–FTC and TDF alone against HIV-1 were not significantly different (P=0.23), and both study medications significantly reduced the HIV-1 incidence among both men and women. The rate of serious adverse events was similar across the study groups. Eight participants receiving active treatment were found to have been infected with HIV-1 at baseline, and among these eight, antiretroviral resistance developed in two during the study.

CONCLUSIONS

Oral TDF and TDF–FTC both protect against HIV-1 infection in heterosexual men and women. (Funded by the Bill and Melinda Gates Foundation; Partners PrEP ClinicalTrials.gov number, NCT00557245.)

THE USE OF ANTIRETROVIRAL MEDICA-tions for the prevention of HIV type 1 (HIV-1) transmission is a promising strategy for reducing the spread of HIV-1.[1-4] Antiretroviral treatment for persons infected with HIV-1 provides important clinical benefits and substantially reduces infectiousness.[5-7] Antiretroviral prophylaxis is a potential HIV-1–prevention strategy for those not yet infected with HIV-1, administered either as postexposure prophylaxis after high-risk occupational or nonoccupational exposure or as preexposure prophylaxis in those with ongoing HIV-1 exposure.[8,9] The rationale for antiretroviral prophylaxis in persons with ongoing exposure is based on its efficacy in infants exposed to HIV-1 during birth and breast-feeding[10] and the partial or full protection it confers against mucosal simian HIV challenge in primates.[11] In perinatal-transmission studies and animal models, the protective benefits of antiretroviral prophylaxis were maximized when the antiretroviral medication was administered both before and after HIV exposure.[12]

The efficacy of preexposure prophylaxis for HIV-1 protection in humans has been evaluated for tenofovir, in the form of a vaginal gel or as oral tenofovir disoproxil fumarate (TDF) or oral TDF coformulated with emtricitabine (TDF–FTC). Studies in animal models suggest that TDF–FTC provides greater protection against HIV-1 than TDF alone.[11] The possibility of differential efficacy, safety, and cost suggests that TDF and TDF–FTC could be compared as potential preexposure prophylaxis agents. Persons at ongoing risk for HIV-1 acquisition in whom preexposure prophylaxis could be studied include persons who are HIV-1–seronegative but are in a partnership with a person already infected with HIV-1 (an HIV-1–serodiscordant partnership).[13,14] We conducted the Partners Preexposure Prophylaxis (PrEP) Study, a multisite, phase 3, randomized, double-blind, three-group, placebo-controlled trial of daily oral TDF or TDF–FTC given as preexposure prophylaxis against HIV-1 acquisition among East African heterosexual men and women in HIV-1–serodiscordant partnerships.

METHODS

STUDY OVERSIGHT

The Bill and Melinda Gates Foundation funded the study but did not oversee the protocol. Gilead Sciences donated the study medication but had no role in data collection, data analysis, or manuscript preparation. All authors vouch for the completeness and accuracy of the data presented.

STUDY POPULATION

From July 2008 through November 2010, we enrolled heterosexual couples in which one partner was infected with HIV-1 and the other partner was not infected (HIV-1–serodiscordant couples) from nine sites in Kenya and Uganda (see Tables S1 and S2 in the Supplementary Appendix, available with the full text of this article at NEJM.org).[15] The HIV-1–seronegative partners had normal renal function, were not infected with hepatitis B virus, and were not pregnant or breast-feeding. The HIV-1–seropositive partners were not receiving antiretroviral therapy and did not meet Kenyan or Ugandan guidelines for initiation of antiretroviral therapy.

The full study protocol and statistical analysis plan are available at NEJM.org. The study protocol was approved by the University of Washington Human Subjects Review Committee and ethics review committees at each of the study sites (see Table S3 in the Supplementary Appendix). All participants provided written informed consent in English or their local language.

RANDOMIZATION AND STUDY PROCEDURES

At enrollment, partners seronegative for HIV-1 were assigned, in a 1:1:1 ratio, to one of the three study groups: once-daily TDF, TDF–FTC, or placebo. Randomization was achieved by means of fixed-size block randomization, with stratification by site. TDF was given at a dose of 300 mg, and FTC was given at a dose of 200 mg; these doses are also the standard for treatment of HIV-1. The study regimens were indistinguishable in appearance, and investigators, except for statistical staff at the central coordinating center, were unaware of the study-group assignments.

All participants received a comprehensive package of HIV-1 prevention services: HIV-1 testing with counseling before and after testing, individual and couples risk-reduction counseling, screening and treatment for sexually transmitted infections, free condoms with training and counseling, and referral for male circumcision and postexposure prophylaxis according to national policies. Vaccination against hepatitis B virus was also offered.

Participants seronegative for HIV-1 had monthly visits that involved HIV-1 testing, dispensation

of 30 days of study medication, collection of the prior month's unused medication, individualized adherence counseling, and standardized assessment of sexual behavior and side effects (see Table S4 in the Supplementary Appendix). Serum chemical and hematologic analyses were performed at 1 month and quarterly thereafter. Women were tested monthly for pregnancy; study medication was withheld in women who became pregnant, and they were referred for antenatal care and allowed to resume study medication when no longer pregnant or lactating.

Partners seropositive for HIV-1 were followed quarterly (see Table S5 in the Supplementary Appendix), with HIV-1 primary care services administered and with CD4 counts obtained every 6 months. Those who became eligible for the initiation of antiretroviral therapy according to national guidelines were actively counseled to initiate treatment and referred to local clinics.

END POINTS

The primary end point was seropositivity in partners previously seronegative for HIV-1. Monthly HIV-1 serologic testing involved two rapid HIV-1 antibody tests in parallel. Study medication was temporarily withheld if either test revealed seroreactivity and was permanently discontinued if enzyme-immunoassay testing confirmed HIV-1 acquisition (see Table S6 in the Supplementary Appendix). For persons with enzyme immunoassay–confirmed acquisition of HIV-1, samples were then tested by HIV-1 Western blotting and RNA polymerase-chain-reaction (PCR) assay at the University of Washington and were adjudicated by an HIV-1 end points committee. Because the study medication was taken by the seronegative partner, HIV-1 sequence analysis to assess transmission within the study partnership was not required for end-point determination and was not performed. For all participants in whom seroconversion occurred, archived plasma samples from visits before seroconversion were tested by means of the HIV-1 RNA PCR assay; those who had detectable HIV-1 RNA in samples from the time of enrollment were excluded with respect to analysis of the primary end point because HIV-1 infection had occurred before randomization.

STATISTICAL ANALYSIS

The study was end-point–driven. We calculated that 147 HIV-1 seroconversion events for each comparison (TDF vs. placebo and TDF–FTC vs. pla-

cebo) would provide 80% power, with a one-sided alpha level of 0.025, to detect a 60% relative decrease in the incidence of HIV-1 infection, with a lower bound of the 95% confidence interval excluding a 30% relative decrease in incidence (the null hypothesis).[15] We further calculated that a sample size of 4700 couples would achieve the target number of study end points, with 24 to 36 months of follow-up per couple and an expected incidence of HIV-1 infection of 2.75 per 100 person-years in the placebo group.[16]

The primary analysis was a modified intention-to-treat analysis, excluding only data from participants with HIV-1 RNA detected in plasma by means of PCR assay at enrollment. We used Cox regression, stratified according to site, to estimate the relative rates of time to first positive HIV-1 serologic test and the Kaplan–Meier method to estimate the cumulative probability of HIV-1 infection.

The study data were reviewed every 6 months by an independent data and safety monitoring board. For statistical monitoring, the Lan–DeMets spending approach was used to adjust the O'Brien–Fleming sequential-monitoring boundaries[17,18]; interim monitoring boundaries were computed by means of S+SeqTrial software (version 2.0, TIBCO). During its closed March 2011 session, the board noted a strong trend toward HIV-1 protection in the active preexposure prophylaxis groups and called an ad hoc meeting for July 10, 2011. At the July meeting, after reviewing data through May 31, 2011, the board recommended that the results of the study be publicly reported and the placebo treatment discontinued, because predetermined stopping rules were met with the demonstration of HIV-1 protection from preexposure prophylaxis. The present analysis includes updated data collected through July 10, 2011. Analyses were conducted using SAS software (version 9.2, SAS Institute).

RESULTS

STUDY PARTICIPANTS

We screened 7856 couples with discordant HIV-1 serostatus. We enrolled 4758 couples and followed 4747: 1584 randomly assigned to TDF, 1579 to TDF–FTC, and 1584 to placebo (Fig. 1). For 62% of the couples followed, the HIV-1–seronegative partner was male (Tables 1 and 2). Among participants seropositive for HIV-1, the median CD4 count was 495 cells per cubic millimeter (inter-

quartile range, 375 to 662), 80% had a CD4 count of 350 cells or more per cubic millimeter, and the median plasma HIV-1 RNA level was 3.9 $\log_{10}$ copies per milliliter (interquartile range, 3.2 to 4.5). Overall, baseline characteristics were similar across the three study groups.

FOLLOW-UP AND ADHERENCE

Retention was 96% or greater during the study period (Fig. 1), with 4722 of the 4747 followed participants (99.5%) completing at least one post-randomization HIV-1 test, for a total of 7830 person-years of follow-up for the assessment of

```
        7856 HIV-1–serodiscordant
          couples were screened
                    │
                    ├──────────→  2892 Were not eligible
                    │             206 Were eligible but not
                    │                 enrolled
                    ↓
        4758 Couples underwent randomization
         ┌──────────┼──────────┐
         ↓          ↓          ↓
1589 Were       1583 Were       1586 Were
assigned to TDF  assigned to     assigned to placebo
                 TDF–FTC
```

1589 Were assigned to TDF	1583 Were assigned to TDF–FTC	1586 Were assigned to placebo
→ 5 Were found to be ineligible	→ 4 Were found to be ineligible	→ 2 Were found to be ineligible
1584 Were included in the intention-to-treat group	1579 Were included in the intention-to-treat group	1584 Were included in the intention-to-treat group
HIV-1–seronegative partners remaining in study 1553/1583 (98%) at 6 mo 1364/1408 (97%) at 12 mo 1076/1112 (97%) at 18 mo 745/778 (96%) at 24 mo 294/306 (96%) at 30 mo 15/15 (100%) at 36 mo	HIV-1–seronegative partners remaining in study 1553/1578 (98%) at 6 mo 1379/1414 (98%) at 12 mo 1070/1106 (97%) at 18 mo 753/784 (96%) at 24 mo 296/309 (96%) at 30 mo 16/16 (100%) at 36 mo	HIV-1–seronegative partners remaining in study 1559/1579 (99%) at 6 mo 1379/1414 (98%) at 12 mo 1083/1111 (97%) at 18 mo 760/783 (97%) at 24 mo 301/308 (98%) at 30 mo 18/18 (100%) at 36 mo
→ 7 Were lost to follow-up 5 Were found to be infected with HIV-1 at enrollment	→ 8 Were lost to follow-up 3 Were found to be infected with HIV-1 at enrollment	→ 10 Were lost to follow-up 6 Were found to be infected with HIV-1 at enrollment
1572 Were included in the primary modified intention-to-treat analysis	1568 Were included in the primary modified intention-to-treat analysis	1568 Were included in the primary modified intention-to-treat analysis

Figure 1. Enrollment and Follow-up of the Study Participants.

The most common reasons for ineligibility were HIV-1–seropositive partners' meeting national criteria for antiretroviral therapy initiation or already taking antiretroviral therapy (59%) and HIV-1–seronegative partners' being pregnant (2%), breast-feeding (0.4%), or having chronic active hepatitis B infection (10%). Less than 3% of ineligible couples met one of the exclusion criteria of creatinine elevation, glycosuria, or proteinuria in the HIV-1–seronegative partner, which were designed to minimize potential renal toxic effects from tenofovir (TDF) exposure. A total of 11 couples were enrolled and randomly assigned to one of the study groups but were later found not to meet all the eligibility criteria; they were discontinued from the study at the time their ineligibility was discovered, and their data were not included in analyses. At least 96% of HIV-1–seropositive partners remained in the study at any point during the follow-up period, and this percentage was similar across the three study groups. FTC denotes emtricitabine.

Table 1. Baseline Characteristics of the Study Participants, According to Study Group and HIV-1 Serostatus.*

Characteristic	TDF (N=1584 couples)		TDF–FTC (N=1579 couples)		Placebo (N=1584 couples)	
	Seronegative Partner	Seropositive Partner	Seronegative Partner	Seropositive Partner	Seronegative Partner	Seropositive Partner
Male sex — no. (%)	986 (62)	598 (38)	1013 (64)	566 (36)	963 (61)	621 (39)
Age — no. (%)						
18–24 yr	184 (12)	268 (17)	177 (11)	287 (18)	172 (11)	273 (17)
25–34 yr	721 (46)	657 (41)	690 (44)	636 (40)	688 (43)	629 (40)
35–44 yr	480 (30)	474 (30)	498 (32)	460 (29)	513 (32)	509 (32)
≥45 yr	199 (13)	185 (12)	214 (14)	196 (12)	211 (13)	173 (11)
Education — yr						
Median	7	7	7	7	7	7
Range	4–10	4–9	4–10	4–9	4–10	4–9
Any monthly income — no. (%)	1275 (80)	1069 (67)	1236 (78)	1052 (67)	1259 (79)	1079 (68)
Any sex with outside partner in prior month — no. (%)	150 (9)	84 (5)	134 (8)	106 (7)	122 (8)	103 (7)
CD4 cell count — cells/mm³						
Median	NA	491	NA	497	NA	499
Range	NA	370–661	NA	380–664	NA	375–663
HIV-1 plasma RNA — $\log_{10}$ copies/ml†						
Median	NA	3.9	NA	3.9	NA	3.9
Range	NA	3.2–4.5	NA	3.1–4.5	NA	3.2–4.5
Circumcised (men only) — no./total no. (%)	533/986 (54)	198/598 (33)	540/1013 (53)	177/566 (31)	509/963 (53)	202/621 (33)
Using contraception (women only) — no./total no. (%)‡	263/598 (44)	290/986 (29)	275/566 (49)	324/1013 (32)	299/621 (48)	321/963 (33)
Pregnant — no./total no. (%)	0/598	152/986 (15)§	0/566	135/1013 (13)	0/621	118/963 (12)
Infection with *Neisseria gonorrhoeae, Chlamydia trachomatis,* or *Trichomonas vaginalis* — no./ total no. (%)¶‖	86/1551 (6)§	117/1520 (8)	93/1557 (6)§	122/1525 (8)	126/1550 (8)	137/1534 (9)
Syphilis seropositivity — no./total no. (%)¶**	59/1569 (4)	73/1576 (5)	60/1572 (4)	52/1573 (3)	62/1569 (4)	73/1571 (5)
HSV-2 seropositivity — no./total no. (%)¶††	835/1506 (55)	NA	814/1507 (54)§	NA	875/1512 (58)	NA

* FTC denotes emtricitabine, HIV-1 HIV type 1, NA not applicable, and TDF tenofovir.

† Plasma HIV-1 RNA concentrations were quantified in enrollment samples by means of batch testing at the University of Washington with the use of the Real-Time HIV-1 RNA assay (Abbott) at a limit of quantification of 80 copies per milliliter.

‡ Contraception includes hormonal oral, injectable, or implantable contraceptive agents; intrauterine devices; and hysterectomy or bilateral tubal ligation. A total of 83% of the HIV-1–seronegative women and 85% of the HIV-1–seropositive women using contraception used a hormonal agent.

§ Results of only four comparisons with the placebo group were significant: prevalence of *Neisseria gonorrhoeae, Chlamydia trachomatis,* or *Trichomonas vaginalis* infection among HIV-1–seronegative partners receiving TDF (6%, vs. 8% receiving placebo; P=0.04) and receiving TDF–FTC (6%, vs. 8% receiving placebo; P=0.02), prevalence of HSV-2 seropositivity among HIV-1–seronegative partners receiving TDF–FTC (54%, vs. 58% receiving placebo; P=0.03); and prevalence of pregnancy among HIV-1–seropositive women receiving TDF (15%, vs. 12% receiving placebo; P=0.04).

¶ Data on sexually transmitted infections were available for more than 95% of participants.

‖ Participants were treated for symptomatic sexually transmitted infections that were found. *T. vaginalis* was the most common infection, accounting for 75% of all the infections detected. *N. gonorrhoeae* and *C. trachomatis* were tested for by different means (APTIMA Combo 2 [Gen-Probe] or COBAS Amplicor [Roche Diagnostics]) than was *T. vaginalis* (APTIMA Trichomonas vaginalis [Gen-Probe] or InPouch TV [BioMed Diagnostics]).

** Syphilis serologic testing was by means of rapid plasma reagin, confirmed with the use of a treponema-specific assay.[15] Seropositivity could indicate current or past infection.

†† Herpes simplex virus type 2 (HSV-2) testing was done by means of the HerpeSelect 2 enzyme immunoassay (Focus Technologies) at enrollment only; an index value of 3.5 or greater was considered a positive result.[19]

Table 2. Baseline Characteristics of the Study Couples, According to Study Group.*

Characteristic	TDF (N=1584)	TDF–FTC (N=1579)	Placebo (N=1584)
Married — no. (%)	1543 (97)	1540 (98)	1552 (98)
Years living together			
Median	7.0	7.1	7.3
Range	3.0–13.5	3.0–14.0	3.0–14.0
Number of children in partnership			
Median	2	2	2
Range	1–4	1–4	1–4
No children — no. (%)	343 (22)	368 (23)	342 (22)
Years aware of HIV-1–serodiscordant status			
Median	0.5	0.4	0.4
Range	0.1–2.0	0.1–2.0	0.1–2.0
Number of sex acts in prior month			
Median	4	4	4
Range	2–8	3–8	2–8
Any unprotected sex acts in prior month — no. (%)	442 (28)	416 (26)	409 (26)

* Characteristics of the couple were reported by the HIV-1–seronegative partner. No comparisons between either treatment group and the placebo group were significant.

HIV-1 incidence accrued (median, 23 months; interquartile range, 16 to 28; range, 1 to 36). Study medication was dispensed at 96% of the attended visits. The most common reason for not dispensing study medication was pregnancy (with an incidence of 11.9, 8.8, and 10.0 pregnancies per 100 woman-years in the TDF, TDF–FTC, and placebo groups, respectively; P>0.05). Time off the study medication due to pregnancy and breast-feeding accounted for 5.3% of the follow-up time among women (2.0% among all participants). Study-medication interruptions for safety-related reasons accounted for less than 1% of the overall follow-up time: 0.6% in the TDF group, 0.7% in the TDF–FTC group, and 0.6% in the placebo group.

The primary study measure of adherence was monthly counts of the returned study bottles and tablets: 98% of the dispensed study bottles were returned, and 97% of dispensed study tablets were taken (see Table S7 in the Supplementary Appendix). Factoring in missed visits, all reasons for nondispensation of study medication, and non-adherence to dispensed study pills, we calculated that study medication was in use during 92.1% of the total follow-up time.

EFFECT OF TDF AND TDF–FTC ON HIV-1 ACQUISITION

HIV-1 seroconversion was observed in 96 participants, of whom 14 had plasma HIV-1 RNA retrospectively detected in specimens obtained at enrollment (5 receiving TDF, 3 receiving TDF–FTC, and 6 receiving placebo) (Fig. 1, and Fig. S1 in the Supplementary Appendix). Of 82 HIV-1 infections developing after randomization, 17 were in the TDF group, 13 were in the TDF–FTC group, and 52 were in the placebo group, indicating relative reductions in the rates of HIV-1 acquisition of 67% due to TDF (95% confidence interval [CI], 44 to 81; P<0.001) and 75% due to TDF–FTC (95% CI, 55 to 87; P<0.001), each relative to placebo (Fig. 2). The HIV-1–protective effects of TDF–FTC and TDF were not significantly different (P=0.23). With both TDF (P=0.003) and TDF–FTC (P<0.001), efficacy of less than 30% was ruled out in the primary modified intention-to-treat analysis. The intention-to-treat analysis including data for participants who were infected with HIV-1 at randomization yielded similar results (Fig. 3).

As compared with placebo, among women, the efficacy of TDF was 71% (P=0.002) and of TDF–FTC 66% (P=0.005); among men, the efficacies were 63% (P=0.01) and 84% (P<0.001), respectively. The HIV-1–protective effects of TDF and TDF–FTC were not statistically different according to sex. Protection against HIV-1 was generally similar between subgroup categories for other prespecified subgroups analyses (Fig. 3). During the follow-up period, 21% of the partners seropositive for HIV-1 (22% in the TDF group, 20% in the TDF–FTC group, and 21% in the placebo group) started combination antiretroviral therapy; the HIV-1–protective effects of TDF and TDF–FTC were similar to those observed in the primary modified intention-to-treat analysis if follow-up time after the HIV-1–seropositive partner started antiretroviral therapy was excluded (see Table S8 in the Supplementary Appendix).

ANTIRETROVIRAL RESISTANCE

Of the 96 persons who had seroconversion to HIV-1 positivity, 92 (96%) had plasma samples available for amplification of the HIV-1 RNA to assess for resistance (Table S9 in the Supplementary Appendix). Among the 8 participants in the TDF and TDF–FTC groups who were found to have been infected at randomization, HIV-1 with resistance to the study medications developed in 2 participants: 1 in the TDF group had a TDF-

Figure 2. Kaplan–Meier Estimates of the Primary End Point in the Modified Intention-to-Treat Analysis, According to Study Treatment.

resistant virus (K65R mutation), and 1 in the TDF–FTC group had an FTC-resistant virus (M184V mutation). No participants who acquired HIV-1 after randomization were infected with an HIV-1 strain with the K65R or M184V mutation.

DETECTION OF TENOFOVIR AND PROPHYLACTIC EFFECT

Among 29 participants in the TDF and TDF–FTC groups who became infected with HIV-1, 31% had a detectable tenofovir level in a plasma sample obtained at the seroconversion visit, as compared with 82% of 902 samples from a random subgroup of 198 participants who did not acquire HIV-1 (Table S10 in the Supplementary Appendix). A detectable level of tenofovir, as compared with an undetectable level of the drug, was associated with estimated reductions in the relative risk of acquiring HIV-1 of 86% (with TDF) and 90% (with TDF–FTC).

SEXUAL BEHAVIOR

At enrollment, 27% of partners seronegative for HIV-1 reported having sex without a condom with their HIV-1–seropositive partner during the prior month. This percentage decreased during

the follow-up period (to 13% and 9% at 12 and 24 months, respectively) and was similar across the study groups (see Fig. S2 in the Supplementary Appendix). The proportions of participants reporting outside partnerships and acquiring sexually transmitted infections during the follow-up period did not differ significantly across the study groups (see Table S11 in the Supplementary Appendix).

SAFETY AND ADVERSE EVENT PROFILES

There were no significant differences in the frequency of deaths, serious adverse events, or serum creatinine or phosphorus abnormalities across the study groups (Table 3, and Table S12 in the Supplementary Appendix). Neutropenia was seen more commonly in the TDF–FTC group (17% of participants with a grade 1 or 2 event and 1% with a grade 3 or 4 event) (see Table S13 in the Supplementary Appendix) than in the TDF group (15% of participants with a grade 1 or 2 event and 1% with a grade 3 or 4 event) or the placebo group (12% of participants with a grade 1 or 2 event and 1% with a grade 3 or 4 event). The active study medications were associated with modestly increased reports of gastrointestinal side effects

Subgroup	TDF	TDF–FTC	Placebo	Hazard Ratio (95% CI), TDF vs. Placebo	P Value	Hazard Ratio (95% CI), TDF–FTC vs. Placebo	P Value
	no. of events/total no. (rate per 100 person-yr)						
Overall							
Modified intention-to-treat population	17/1579 (0.65)	13/1576 (0.50)	52/1578 (1.99)	0.33 (0.19–0.56)	<0.001	0.25 (0.13–0.45)	<0.001
Intention-to-treat population	22/1584 (0.84)	16/1579 (0.61)	58/1584 (2.22)	0.38 (0.23–0.62)	<0.001	0.27 (0.16–0.48)	<0.001
Sex of HIV-1–seronegative partner					0.65		0.24
Male	9/984 (0.56)	4/1010 (0.24)	24/959 (1.49)	0.37 (0.17–0.80)		0.16 (0.06–0.46)	
Female	8/595 (0.81)	9/566 (0.95)	28/619 (2.81)	0.29 (0.13–0.63)		0.34 (0.16–0.72)	
Age of HIV-1–seronegative partner					0.79		0.06
<25 yr	3/184 (1.07)	6/177 (2.34)	10/170 (4.04)	0.28 (0.08–1.01)		0.59 (0.21–1.61)	
≥25 yr	14/1395 (0.60)	7/1399 (0.30)	42/1408 (1.78)	0.34 (0.18–0.61)		0.17 (0.07–0.37)	
Unprotected sex with study partner during past mo					0.05		0.77
No	14/1138 (0.72)	8/1161 (0.40)	30/1170 (1.50)	0.47 (0.25–0.89)		0.27 (0.12–0.58)	
Yes	3/441 (0.46)	5/415 (0.78)	22/408 (3.60)	0.13 (0.04–0.44)		0.22 (0.08–0.58)	
Country					0.94		0.46
Kenya	7/699 (0.61)	7/697 (0.60)	22/694 (1.90)	0.32 (0.14–0.74)		0.31 (0.13–0.74)	
Uganda	10/880 (0.69)	6/879 (0.41)	30/884 (2.07)	0.33 (0.16–0.68)		0.20 (0.08–0.48)	
Circumcision status of HIV-1–seronegative men					0.54		0.42
Circumcised	6/542 (0.70)	3/543 (0.34)	13/512 (1.52)	0.46 (0.17–1.20)		0.22 (0.06–0.79)	
Uncircumcised	3/440 (0.40)	1/467 (0.12)	11/447 (1.45)	0.28 (0.08–1.00)		0.09 (0.01–0.68)	
Plasma HIV-1 RNA level of HIV-1–seropositive partner					0.39		0.79
<50,000 copies/ml	13/1277 (0.61)	9/1279 (0.42)	32/1263 (1.51)	0.40 (0.21–0.76)		0.28 (0.13–0.58)	
≥50,000 copies/ml	4/269 (0.90)	4/271 (0.90)	18/289 (3.93)	0.23 (0.08–0.69)		0.23 (0.08–0.68)	
CD4 count of HIV-1–seropositive partner					0.03		0.39
250–349 cells/mm³	8/312 (1.56)	4/297 (0.78)	10/299 (1.95)	0.79 (0.31–2.01)		0.39 (0.12–1.26)	
≥350 cells/mm³	9/1267 (0.43)	9/1279 (0.43)	42/1279 (2.01)	0.21 (0.10–0.44)		0.21 (0.10–0.44)	

Figure 3. Hazard Ratios for HIV-1 Infection Overall and among Subgroups, According to Study Group.

P values for the modified intention-to-treat and the intention-to-treat analyses are for the hypothesis of any evidence of efficacy (i.e., testing against a null hypothesis of 0%); P values for the other comparisons correspond to a test for significant interaction in the site-stratified Cox proportional-hazards model. Of 45 HIV-1 infections in women, 5 occurred in women (2 in the TDF group and 3 in the placebo group) who had not received study medication for more than 3 months owing to pregnancy or breast-feeding.

Table 3. Adverse Events, According to Study Group.*

Adverse Event	TDF (N=1584)	P Value vs. Placebo	TDF–FTC (N=1579)	P Value vs. Placebo	Placebo (N=1584)
	no. (%)		no. (%)		no. (%)
Any adverse event	1350 (85)	1.00	1362 (86)	0.42	1350 (85)
Any serious adverse event	118 (7)	1.00	115 (7)	0.89	118 (7)
Death†	8 (1)	0.80	8 (1)	0.80	9 (1)
Any grade 4 event	34 (2)	0.64	44 (3)	0.58	39 (3)
Any grade 3 event	289 (18)	0.35	293 (19)	0.24	268 (17)
Confirmed laboratory events‡					
Elevated creatinine§					
Grade 1	16 (1)	0.57	18 (1)	0.28	12 (1)
Grade 2 or 3	3 (<1)	0.62	2 (<1)	0.62	1 (<1)
Decreased phosphorus¶					
Grade 2	134 (8)	0.56	128 (8)	0.79	124 (8)
Grade 3	8 (1)	0.50	12 (1)	1.00	12 (1)

* All clinical adverse events of grade 2 or higher and all confirmed laboratory adverse events that were reported in 1% or more (≥47) of study participants are listed in Table S9 in the Supplementary Appendix. P values were calculated with the use of Fisher's exact test except for those for death, which were calculated by means of the Cox proportional-hazards model of time to death.
† In the TDF group, two participants died from trauma, two from alcohol poisoning, and one each from esophageal carcinoma, lung abscess, shigella gastroenteritis, and acute abdomen. In the TDF–FTC group, three participants died from trauma and one each from poisoning, pulmonary embolism, pulmonary tuberculosis, gastroenteritis, and acute febrile illness. In the placebo group, three participants died from trauma and one each from electrocution, suicide, hematemesis, complications of diabetes, febrile illness, and hypotension.
‡ Laboratory adverse events are reported here only if they were confirmed by means of repeat testing, ideally conducted within 7 days after the event.
§ One confirmed grade 3 case of elevated creatinine was observed in the study, in a 46-year-old male participant receiving TDF who had seroconversion to HIV-1 seropositivity and had discontinued study medication 22 days previously. The creatinine level returned to normal after hydration. No confirmed grade 4 creatinine events were observed.
¶ According to the study protocol, there was no grade 1 decrease in phosphorus level, and no confirmed grade 4 phosphorus decreases were observed. Clinically significant proteinuria (≥grade 1) was observed in association with 27 confirmed grade 2 phosphorus decreases (nine participants in each of the three study groups) and 1 confirmed grade 3 event (in the placebo group). Glycosuria of grade 1 or greater was observed in association with 7 confirmed grade 2 phosphorus decreases (two participants each in the TDF and placebo groups and three in the TDF–FTC group) and 2 confirmed grade 3 events (one each in the TDF and placebo groups).

and fatigue as compared with placebo, primarily during the first month of administration (see Table S14 in the Supplementary Appendix).

DISCUSSION

In this study of heterosexual men and women with a partner known to have HIV-1 infection, once-daily oral TDF and TDF–FTC were associated with risk reductions of 67% and 75%, respectively, against HIV-1 infection when provided in conjunction with other HIV-1 prevention services. Both TDF and TDF–FTC showed significant, and a similar magnitude of, HIV-1 protection for both women and men.

Clinical trials of tenofovir-based preexposure prophylaxis have had conflicting results. Once-daily oral TDF–FTC reduced the risk of HIV-1 acquisition by 44% in a multicountry study among men who have sex with men and by 62% among young heterosexuals from Botswana,[20,21] and the use of 1% tenofovir vaginal gel decreased the incidence of HIV-1 among South African women by 39%.[22] Biologic and behavioral hypotheses have been proposed to explain the failure of two trials of preexposure prophylaxis among African women to show protection against HIV-1 infection,[23,24] including a lack of adherence to daily doses of preexposure prophylaxis, vaginal concentrations of tenofovir achieved with oral dosing that may be particularly sensitive to nonadherence,[25] sexually transmitted infections or other cofactors

affecting infection with HIV-1 in young women, high HIV-1 concentrations in the seropositive partner during primary HIV-1 infection, and innate or acquired immunologic factors that may provide adjunctive protection in long-term couples with HIV-1 serodiscordance. Further study is needed to understand which, if any, of these factors influence the efficacy of preexposure prophylaxis.

Although we studied established couples known to be HIV-1–serodiscordant, all HIV-1 transmissions ultimately occur between serodiscordant partners. Our findings provide proof of concept that preexposure prophylaxis can reduce HIV-1 acquisition in heterosexual populations.

High adherence is essential to achieve clinical benefits from antiretroviral agents for HIV-1 treatment,[26] and emerging evidence suggests that adherence to preexposure prophylaxis is also important for HIV-1 prevention. In the Preexposure Prophylaxis Initiative trial involving men who have sex with men, the relative reduction in the risk of HIV-1 infection from TDF–FTC preexposure prophylaxis was 44% overall but was 73% among the participants with an adherence of 90% or more (as measured by means of pill counts) and 92% among the participants with detectable tenofovir levels in the blood — although only half the participants had detectable levels.[20]

In our study, retention and pill-count adherence were high, tenofovir was detected in 82% of samples from randomly selected participants, and detectable tenofovir levels were associated with a reduction in the relative risk of HIV-1 infection of more than 85%. The high proportion of samples with detectable tenofovir levels is consistent with the 92% study-drug coverage we calculated on the basis of missed visits, withholding of the study drug, and nonadherence, with the absolute difference of 10 percentage points most likely reflecting the fact that pill counts can overestimate adherence if pills are not returned.

Analyses of objective adherence measures across preexposure prophylaxis trials will be informative for understanding the relationship between adherence and protection against HIV-1 infection. In a subgroup of our study cohort, intensive monitoring of adherence by means of pill bottles with caps that electronically monitor bottle openings and monthly unannounced visits to the home for purposes of pill counting supported high adherence,[27] and in-depth interviews have emphasized that trust and the support of a partner reinforce high adherence.[28] Strategies to promote and achieve high adherence outside clinical-trial settings will be necessary to achieve maximum public health benefits of preexposure prophylaxis.

We found similar degrees of protection against HIV-1 with TDF and TDF–FTC, in contrast to findings in studies of animal models.[11] Dual-agent preexposure prophylaxis would most likely be more expensive than single-agent preexposure prophylaxis, and the potential for differential tolerability and antiretroviral resistance in persons with HIV-1 seroconversion despite the use of preexposure prophylaxis should be considered in decision making with regard to public health policies regarding preexposure prophylaxis. We are continuing the TDF and TDF–FTC groups of our study, including offering randomization to TDF or TDF–FTC to participants originally assigned to the placebo group, to gather additional information on the relative safety, efficacy, and HIV-1 resistance of TDF as compared with TDF–FTC.

In our study, 25% (two of eight) of participants who had acute HIV-1 infection at the time of study-drug initiation had viral resistance develop (through the M184V mutation in one and the K65R mutation in the other). The initiation of preexposure or postexposure prophylaxis in persons with acute HIV-1 infection can select for resistance; strategies to improve the recognition of acute infection are needed.[20,29,30] Resistance was rare in partners in whom seroconversion occurred after randomization, of whom a minority had detectable tenofovir levels.

Adherence to preexposure prophylaxis, protection against HIV-1 infection, and antiretroviral resistance appear to be tightly interwoven. Low adherence provides little HIV-1 protection but little risk of resistance if infection is acquired. High adherence potentially blocks most transmissions, and the few persons who acquire HIV-1 despite preexposure prophylaxis potentially have an increased risk of drug resistance. Four participants with HIV-1 seroconversion in our study became infected with HIV-1 that was resistant to nonnucleoside reverse-transcriptase inhibitors, which should not have been selected for by the study medication and instead probably reflects circulating resistance, which is increasingly being detected in Africa.[31]

When used for HIV-1 treatment, TDF is known to cause small decreases in glomerular filtration that are of uncertain clinical significance.[32] In

our population of HIV-1–seronegative participants without preexisting renal impairment, we found no evidence of clinically significant elevations in serum creatinine. Additional studies are needed of proximal renal tubular function, bone mineral density, and other aspects of long-term safety of TDF-based preexposure prophylaxis, as well as safety in pregnant, breast-feeding, or adolescent women, among whom HIV-1 rates are high.[33,34]

For couples known to have HIV-1 serodiscordance, antiretroviral treatment of the partner infected with HIV-1 provides substantial, though incomplete, protection against HIV-1 transmission; 25 to 30% of HIV-1 infection in serodiscordant couples are from infected partners outside the couple.[5,7] Mathematical modeling may help guide policy decisions regarding optimal targeting and timing of treatment and preexposure prophylaxis for reducing HIV-1 incidence in couples.[35] Antiretroviral-based HIV-1–prevention strategies may be particularly important for couples seeking to have children.[36-38] In addition, preexposure prophylaxis offers an HIV-1 prevention strategy for uninfected persons with partners who do not know their HIV-1 status or who are infected with HIV-1 but have not begun antiretroviral therapy.

Successful prevention of HIV-1 infection on a population scale will need to incorporate multiple, evidence-based biomedical and behavioral strategies to achieve maximum benefits. The HIV-1 incidence in this study was lower than that seen in previous studies of HIV-1–serodiscordant African couples,[14,39] emphasizing the importance of and synergy among HIV-1 testing in individuals and couples, risk-reduction counseling, and other prevention services, in combination with antiretroviral preexposure prophylaxis, for reducing the risk of HIV-1 infection in heterosexual populations. Potential implementation of preexposure prophylaxis as a public health measure will require clinical monitoring, methods for encouraging adherence, and ensured access to antiretroviral therapy for HIV-1–infected persons. Nonetheless, to stem the global HIV-1 epidemic, effective primary HIV-1 prevention strategies are critical.

APPENDIX

The authors' full names and degrees are as follows: Jared M. Baeten, M.D., Ph.D., Deborah Donnell, Ph.D., Patrick Ndase, M.B., Ch.B., M.P.H., Nelly R. Mugo, M.B., Ch.B., M.P.H., James D. Campbell, M.D., Jonathan Wangisi, M.B., Ch.B., Jordan W. Tappero, M.D., M.P.H., Elizabeth A. Bukusi, M.B., Ch.B., Ph.D., Craig R. Cohen, M.D., M.P.H., Elly Katabira, M.B., Ch.B., Allan Ronald, M.D., Elioda Tumwesigye, M.B., Ch.B., Edwin Were, M.B., Ch.B., M.P.H., Kenneth H. Fife, M.D., Ph.D., James Kiarie, M.B., Ch.B., M.P.H., Carey Farquhar, M.D., M.P.H., Grace John-Stewart, M.D., Ph.D., Aloysious Kakia, M.B., Ch.B., Josephine Odoyo, M.P.H., Akasiima Mucunguzi, M.B., Ch.B., Edith Nakku-Joloba, M.B., Ch.B., Ph.D., Rogers Twesigye, M.B., Ch.B., M.P.H., Kenneth Ngure, Ph.D., Cosmas Apaka, B.Sc., Harrison Tamooh, M.B., Ch.B., Fridah Gabona, M.B., Ch.B., Andrew Mujugira, M.B., Ch.B., Dana Panteleeff, B.S., Katherine K. Thomas, M.S., Lara Kidoguchi, M.P.H., Meighan Krows, B.A., Jennifer Revall, B.A., Susan Morrison, M.D., M.P.H., Harald Haugen, M.S., Mira Emmanuel-Ogier, B.A., Lisa Ondrejcek, M.A., Robert W. Coombs, M.D., Ph.D., Lisa Frenkel, M.D., Craig Hendrix, M.D., Namandjé N. Bumpus, Ph.D., David Bangsberg, M.D., M.P.H., Jessica E. Haberer, M.D., M.P.H., Wendy S. Stevens, M.D., F.C.Path., Jairam R. Lingappa, M.D., Ph.D., and Connie Celum, M.D., M.P.H.

The authors' affiliations are as follows: the Departments of Global Health (J.M.B., D.D., P.N., N.R.M., E.A.B., J.K., C.F., G.J.-S., A. Mujugira, D.P., K.K.T., L.K., M.K., J.R., S.M., H.H., M.E.-O., J.R.L., C.C.), Medicine (J.M.B., C.F., G.J.-S., R.W.C., J.R.L., C.C.), Epidemiology (J.M.B., C.F., G.J.-S., C.C.), Laboratory Medicine (R.W.C., L.F.), and Pediatrics (L.F., J.R.L.), University of Washington, the Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center (D.D.), DF/Net Research (L.O.), and Seattle Children's Hospital Research Institute (L.F.) — all in Seattle; the Department of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital, Nairobi (N.R.M., E.A.B., J.K., K.N., H.T.), the Center for Microbiology Research, Kenya Medical Research Institute, Nairobi (E.A.B., J.O.), and the Department of Reproductive Health, Moi University, Eldoret (E.W., C.A.) — all in Kenya; the Centers for Disease Control and Prevention, Entebbe (J.D.C.), the AIDS Support Organization (J.W., A.K., A. Mucunguzi) and the Infectious Disease Institute, Makerere University (E.K., A.R., E.N.-J., F.G.), Kampala, and the Kabwohe Clinical Research Center, Kabwohe (E.T., R.T.) — all in Uganda; the Centers for Disease Control and Prevention, Atlanta (J.W.T.); the Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco (E.A.B., C.R.C.); the Department of Medicine, University of Manitoba, Winnipeg, Canada (A.R.); the Department of Medicine, Indiana University, Indianapolis (K.H.F.); the Department of Medicine, Johns Hopkins University, Baltimore (C.H., N.B.); Massachusetts General Hospital and Harvard Medical School, Boston (D.B., J.E.H.); and the Department of Molecular Medicine and Hematology, University of the Witwatersrand, and Contract Laboratory Services, Wits Health Consortium, Johannesburg, South Africa (W.S.).

409

REFERENCES

1. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591-601.
2. Karim SS, Karim QA. Antiretroviral prophylaxis: a defining moment in HIV control. Lancet 2011;378(9809):e23-e25.
3. Padian NS, McCoy SI, Karim SS, et al. HIV prevention transformed: the new prevention research agenda. Lancet 2011;378: 269-78.
4. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010;376:532-9.
5. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010;375: 2092-8.
6. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009;23:1397-404.
7. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
8. Grant RM. Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis 2010;50:Suppl 3:S96-S101.
9. Oral and topical PrEP trials timeline. New York: AVAC: Global Advocacy for HIV Prevention, 2011 (http://www.avac.org/prep).
10. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008;359:119-29.
11. García-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008;5(2):e28.
12. García-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010; 2(14):14ra4.
13. Eyawo O, de Walque D, Ford N, Gakii G, Lester RT, Mills EJ. HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:770-7.
14. Dunkle KL, Stephenson R, Karita E, et al. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 2008;371:2183-91.

15. Mujugira A, Baeten JM, Donnell D, et al. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One 2011;6(10): e25828.
16. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010;362:427-39.
17. Lan K, Gordan K, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
18. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
19. Laeyendecker O, Henson C, Gray RH, et al. Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol 2004;42:1794-6.
20. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.
21. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367: 423-34.
22. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-74. [Erratum, Science 2011;333:524.]
23. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411-22.
24. NIH modifies 'VOICE' HIV prevention study in women: oral tenofovir discontinued in clinical trial. Bethesda, MD: National Institute of Allergy and Infectious Diseases, September 28, 2011 (http://www.nih.gov/news/health/sep2011/niaid-28.htm).
25. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 2011;378:279-81.
26. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006;296:679-90.
27. Haberer J, Baeten J, Celum C, et al. Near perfect early adherence to antiretroviral PrEP against HIV infection among HIV serodiscordant couples as determined by multiple measures: preliminary data from the Partners PrEP Study. Presented at the 18th Conference on Retroviruses

and Opportunistic Infections, Boston, February 27–March 2, 2011. abstract.
28. Ware NC, Wyatt MA, Haberer JE, et al. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr 2012;59:463-8.
29. Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005;41:1507-13.
30. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998;339:33-9.
31. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011;11:750-9.
32. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51:496-505.
33. Mugo NR, Heffron R, Donnell D, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1 serodiscordant couples. AIDS 2011;25:1887-95.
34. Rehle TM, Hallett TB, Shisana O, et al. A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLoS One 2010;5(6):e11094.
35. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011;8(11):e1001123.
36. Matthews LT, Baeten JM, Celum C, Bangsberg DR. Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS 2010;24:1975-82.
37. Vernazza PL, Graf I, Sonnenberg-Schwan U, Geit M, Meurer A. Pre-exposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. AIDS 2011;25:2005-8.
38. Lampe MA, Smith DK, Anderson GJ, Edwards AE, Nesheim SR. Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol 2011;204(6):488.e1-488.e8.
39. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-9.
Copyright © 2012 Massachusetts Medical Society.